Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Atanasova

Showing results (31-40 of 42) with videos related to

Pageof 5
Sort By:
International Journal of Molecular Sciences|January 21, 2023
Selective Eradication of Colon Cancer Cells Harboring PI3K and/or MAPK Pathway Mutations in 3D Culture by Combined PI3K/AKT/mTOR Pathway and MEK InhibitionVelina S Atanasova, Angelika Riedl, Marcus Strobl, et al.
Clinical and Experimental Dermatology|February 24, 2018
Seven novel COL7A1 mutations identified in patients with recessive dystrophic epidermolysis bullosa from MexicoA H Saeidian, L Youssefian, M G Moreno Trevino, et al.
The Journal of Investigative Dermatology|May 28, 2017
Amlexanox Enhances Premature Termination Codon Read-Through in COL7A1 and Expression of Full Length Type VII Collagen: Potential Therapy for Recessive Dystrophic Epidermolysis BullosaVelina S Atanasova, Qiujie Jiang, Marco Prisco, et al.
RNA Biology|March 9, 2013
Snapshot of haloarchaeal tailed virus genomesAna Senčilo, Deborah Jacobs-Sera, Daniel A Russell, et al.
The Journal of Investigative Dermatology|January 27, 2019
Thrombospondin-1 Is a Major Activator of TGF-β Signaling in Recessive Dystrophic Epidermolysis Bullosa FibroblastsVelina S Atanasova, Rebecca J Russell, Timothy G Webster, et al.
Molecular Oncology|March 11, 2025
The atypical KRAS<sup>Q22K</sup> mutation directs TGF-β response towards partial epithelial-to-mesenchymal transition in patient-derived colorectal cancer tumoroidsTheresia Mair, Philip König, Milena Mijović, et al.
Journal for Immunotherapy of Cancer|November 5, 2024
Cancer-associated fibroblasts shape early myeloid cell response to chemotherapy-induced immunogenic signals in next generation tumor organoid culturesJulijan Kabiljo, Anna Theophil, Jakob Homola, et al.
Indoor Air|October 28, 2022
SARS-CoV-2 indoor environment contamination with epidemiological and experimental investigationsLotta-Maria A H Oksanen, Jenni Virtanen, Enni Sanmark, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 9, 2019
Identification of Rigosertib for the Treatment of Recessive Dystrophic Epidermolysis Bullosa-Associated Squamous Cell CarcinomaVelina S Atanasova, Celine Pourreyron, Mehdi Farshchian, et al.
Cellular and Molecular Gastroenterology and Hepatology|March 3, 2023
Mimicking Tumor Cell Heterogeneity of Colorectal Cancer in a Patient-derived Organoid-Fibroblast ModelVelina S Atanasova, Crhistian de Jesus Cardona, Václav Hejret, et al.
Pageof 5

Showing results (31-40 of 42) with videos related to

Sort By:
Pageof 5
International Journal of Molecular Sciences|January 21, 2023
Selective Eradication of Colon Cancer Cells Harboring PI3K and/or MAPK Pathway Mutations in 3D Culture by Combined PI3K/AKT/mTOR Pathway and MEK InhibitionVelina S Atanasova, Angelika Riedl, Marcus Strobl, et al.
Clinical and Experimental Dermatology|February 24, 2018
Seven novel COL7A1 mutations identified in patients with recessive dystrophic epidermolysis bullosa from MexicoA H Saeidian, L Youssefian, M G Moreno Trevino, et al.
The Journal of Investigative Dermatology|May 28, 2017
Amlexanox Enhances Premature Termination Codon Read-Through in COL7A1 and Expression of Full Length Type VII Collagen: Potential Therapy for Recessive Dystrophic Epidermolysis BullosaVelina S Atanasova, Qiujie Jiang, Marco Prisco, et al.
RNA Biology|March 9, 2013
Snapshot of haloarchaeal tailed virus genomesAna Senčilo, Deborah Jacobs-Sera, Daniel A Russell, et al.
The Journal of Investigative Dermatology|January 27, 2019
Thrombospondin-1 Is a Major Activator of TGF-β Signaling in Recessive Dystrophic Epidermolysis Bullosa FibroblastsVelina S Atanasova, Rebecca J Russell, Timothy G Webster, et al.
Molecular Oncology|March 11, 2025
The atypical KRAS<sup>Q22K</sup> mutation directs TGF-β response towards partial epithelial-to-mesenchymal transition in patient-derived colorectal cancer tumoroidsTheresia Mair, Philip König, Milena Mijović, et al.
Journal for Immunotherapy of Cancer|November 5, 2024
Cancer-associated fibroblasts shape early myeloid cell response to chemotherapy-induced immunogenic signals in next generation tumor organoid culturesJulijan Kabiljo, Anna Theophil, Jakob Homola, et al.
Indoor Air|October 28, 2022
SARS-CoV-2 indoor environment contamination with epidemiological and experimental investigationsLotta-Maria A H Oksanen, Jenni Virtanen, Enni Sanmark, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 9, 2019
Identification of Rigosertib for the Treatment of Recessive Dystrophic Epidermolysis Bullosa-Associated Squamous Cell CarcinomaVelina S Atanasova, Celine Pourreyron, Mehdi Farshchian, et al.
Cellular and Molecular Gastroenterology and Hepatology|March 3, 2023
Mimicking Tumor Cell Heterogeneity of Colorectal Cancer in a Patient-derived Organoid-Fibroblast ModelVelina S Atanasova, Crhistian de Jesus Cardona, Václav Hejret, et al.
Pageof 5